Back to Search
Start Over
Neurocognition in the Psychosis Risk Syndrome: A Quantitative and Qualitative Review
- Source :
- Current Pharmaceutical Design. 18:399-415
- Publication Year :
- 2012
- Publisher :
- Bentham Science Publishers Ltd., 2012.
-
Abstract
- Cognitive dysfunction is a hallmark feature of schizophrenia and is evident across all phases of the illness. While prior meta-analyses have elucidated the level and pattern of cognitive deficits in the premorbid and post-onset periods of psychosis, no meta-analyses of studies of the putative prodromal period have been published. Our primary aim is to provide a meta-analysis of neurocognitive findings from 14 studies of psychosis risk syndrome (PRS) individuals published through February 2011, and compare the resulting profile with that synthesized by meta-analyses from other periods of the disorder. Meta-analysis of 1215 PRS individuals with a mean age of 19.2 (± 3.3) and 851 healthy control subjects yielded small-to-medium impairments across nine of 10 neurocognitive domains (Cohen's d = -0.26 to -0.67). Seven studies reported on PRS individuals who later developed psychosis (n = 175) and their baseline performance level generally yielded moderate-to-large ESs (d = -0.35 to -0.84). Mild cognitive deficits are reliably and broadly present in PRS individuals, falling at a level that is intermediate between healthy individuals and those diagnosed with schizophrenia, and at a level that is comparable to those at familial ("genetic") risk and with premorbid data. Moreover, baseline neurocognition in PRS individuals who converted to psychosis showed more severe deficits than non-converters in nearly all domains. However, considerable heterogeneity of ESs across studies in many domains underscores variability in phenotypic expression and/or measurement sensitivity, and a critical need for improved reporting of sample characteristics to support moderator variable analyses.
- Subjects :
- Pharmacology
Clinical Trials as Topic
Psychosis
Prodromal Period
medicine.medical_specialty
business.industry
Cognition
Syndrome
medicine.disease
Moderation
Psychotic Disorders
Risk Factors
Schizophrenia
Meta-analysis
Drug Discovery
Schizophrenic Psychology
Disease Progression
medicine
Humans
Cognition Disorders
Psychiatry
business
Neurocognitive
Subjects
Details
- ISSN :
- 13816128
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Current Pharmaceutical Design
- Accession number :
- edsair.doi.dedup.....437ae7ac380516e87ac052d3fc0f3b69
- Full Text :
- https://doi.org/10.2174/138161212799316019